Literature DB >> 17484729

Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab.

J Schulze, M Rose, S Zielen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17484729     DOI: 10.1111/j.1398-9995.2007.01388.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


× No keyword cloud information.
  14 in total

Review 1.  [Pharmacoprophylaxis and co-medications in allergen-specific immunotherapy].

Authors:  B Wedi; F Ruëff
Journal:  Hautarzt       Date:  2011-09       Impact factor: 0.751

2.  [Intolerance of specific immunotherapy with Hymenoptera venom: jumping the hurdle with omalizumab].

Authors:  D Wieczorek; A Kapp; B Wedi
Journal:  Hautarzt       Date:  2014-09       Impact factor: 0.751

3.  Omalizumab: A useful tool for inducing tolerance to bee venom immunotherapy.

Authors:  L Ricciardi
Journal:  Int J Immunopathol Pharmacol       Date:  2016-09-27       Impact factor: 3.219

4.  International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Authors:  Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek
Journal:  Int Forum Allergy Rhinol       Date:  2018-02       Impact factor: 3.858

Review 5.  Advances in anti-IgE therapy.

Authors:  Arzu Didem Yalcin
Journal:  Biomed Res Int       Date:  2015-05-05       Impact factor: 3.411

Review 6.  An overview of the effects of anti-IgE therapies.

Authors:  Arzu Didem Yalcin
Journal:  Med Sci Monit       Date:  2014-09-22

7.  Anti-immunoglobulin e therapy.

Authors:  Manav Segal; Jeffrey R Stokes; Thomas B Casale
Journal:  World Allergy Organ J       Date:  2008-10       Impact factor: 4.084

8.  Exercise-induced anaphylaxis: a case report and review of the diagnosis and treatment of a rare but potentially life-threatening syndrome.

Authors:  Nathan T Jaqua; Matthew R Peterson; Karla L Davis
Journal:  Case Rep Med       Date:  2013-03-27

Review 9.  [Venom immunotherapy. Side effects and efficacy of treatment].

Authors:  F Ruëff; B Przybilla
Journal:  Hautarzt       Date:  2008-03       Impact factor: 1.198

10.  Omalizumab, an anti-immunoglobulin E antibody: state of the art.

Authors:  Cristoforo Incorvaia; Marina Mauro; Marina Russello; Chiara Formigoni; Gian Galeazzo Riario-Sforza; Erminia Ridolo
Journal:  Drug Des Devel Ther       Date:  2014-02-07       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.